The new era of anticoagulation: factor XI and XII inhibitors
The two last decades have witnessed a revolution in the field of anticoagulation, mainly due to the advent of direct anticoagulant with targeted action against single coagulation proteins. However, the residual risk of cardio- and cerebrovascular events, particularly in some critical settings, and...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2023-06-01
|
| Series: | Bleeding, Thrombosis and Vascular Biology |
| Subjects: | |
| Online Access: | https://btvb.org/btvb/article/view/76 |
| _version_ | 1797809112771198976 |
|---|---|
| author | Domenico Prisco Irene Mattioli Raffaele De Caterina Alessandra Bettiol |
| author_facet | Domenico Prisco Irene Mattioli Raffaele De Caterina Alessandra Bettiol |
| author_sort | Domenico Prisco |
| collection | DOAJ |
| description |
The two last decades have witnessed a revolution in the field of anticoagulation, mainly due to the advent of direct anticoagulant with targeted action against single coagulation proteins. However, the residual risk of cardio- and cerebrovascular events, particularly in some critical settings, and the risk of major bleeding still represent unmet medical needs. Preclinical studies and experience from families with genetic deficiencies of factor XI or XII (FXI and FXII) allowed to identify these factors involved in the contact pathway of coagulation as potential targets for new anticoagulant approaches. To date, several pharmacological classes of FXI and FXII inhibitors have been developed, including antisense oligonucleotides, monoclonal antibodies, small molecules, natural inhibitors, and aptamers, and various molecules are currently under phase 2 or 3 clinical investigation. Particularly, promising results have been obtained in patients undergoing major orthopedic surgery, in those with end-stage kidney disease, atrial fibrillation and acute coronary syndrome. This review summarizes current knowledge on FXI and FXII inhibitors, with a particular focus on their pharmacological properties and potential clinical indications.
|
| first_indexed | 2024-03-13T06:47:44Z |
| format | Article |
| id | doaj.art-c642306a27ce4e6eb3b5091735224e06 |
| institution | Directory Open Access Journal |
| issn | 2785-5309 |
| language | English |
| last_indexed | 2024-03-13T06:47:44Z |
| publishDate | 2023-06-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Bleeding, Thrombosis and Vascular Biology |
| spelling | doaj.art-c642306a27ce4e6eb3b5091735224e062023-06-08T05:08:45ZengPAGEPress PublicationsBleeding, Thrombosis and Vascular Biology2785-53092023-06-012210.4081/btvb.2023.76The new era of anticoagulation: factor XI and XII inhibitorsDomenico Prisco0Irene Mattioli1Raffaele De Caterina2Alessandra Bettiol3Department of Experimental and Clinical Medicine, University of Florence; Careggi University Hospital, FlorenceDepartment of Experimental and Clinical Medicine, University of FlorenceDivision of Cardiology, Pisa University Hospital and University of PisaDepartment of Experimental and Clinical Medicine, University of Florence The two last decades have witnessed a revolution in the field of anticoagulation, mainly due to the advent of direct anticoagulant with targeted action against single coagulation proteins. However, the residual risk of cardio- and cerebrovascular events, particularly in some critical settings, and the risk of major bleeding still represent unmet medical needs. Preclinical studies and experience from families with genetic deficiencies of factor XI or XII (FXI and FXII) allowed to identify these factors involved in the contact pathway of coagulation as potential targets for new anticoagulant approaches. To date, several pharmacological classes of FXI and FXII inhibitors have been developed, including antisense oligonucleotides, monoclonal antibodies, small molecules, natural inhibitors, and aptamers, and various molecules are currently under phase 2 or 3 clinical investigation. Particularly, promising results have been obtained in patients undergoing major orthopedic surgery, in those with end-stage kidney disease, atrial fibrillation and acute coronary syndrome. This review summarizes current knowledge on FXI and FXII inhibitors, with a particular focus on their pharmacological properties and potential clinical indications. https://btvb.org/btvb/article/view/76Anticoagulationbleedingfactor XIfactor XIIthrombosis |
| spellingShingle | Domenico Prisco Irene Mattioli Raffaele De Caterina Alessandra Bettiol The new era of anticoagulation: factor XI and XII inhibitors Bleeding, Thrombosis and Vascular Biology Anticoagulation bleeding factor XI factor XII thrombosis |
| title | The new era of anticoagulation: factor XI and XII inhibitors |
| title_full | The new era of anticoagulation: factor XI and XII inhibitors |
| title_fullStr | The new era of anticoagulation: factor XI and XII inhibitors |
| title_full_unstemmed | The new era of anticoagulation: factor XI and XII inhibitors |
| title_short | The new era of anticoagulation: factor XI and XII inhibitors |
| title_sort | new era of anticoagulation factor xi and xii inhibitors |
| topic | Anticoagulation bleeding factor XI factor XII thrombosis |
| url | https://btvb.org/btvb/article/view/76 |
| work_keys_str_mv | AT domenicoprisco theneweraofanticoagulationfactorxiandxiiinhibitors AT irenemattioli theneweraofanticoagulationfactorxiandxiiinhibitors AT raffaeledecaterina theneweraofanticoagulationfactorxiandxiiinhibitors AT alessandrabettiol theneweraofanticoagulationfactorxiandxiiinhibitors AT domenicoprisco neweraofanticoagulationfactorxiandxiiinhibitors AT irenemattioli neweraofanticoagulationfactorxiandxiiinhibitors AT raffaeledecaterina neweraofanticoagulationfactorxiandxiiinhibitors AT alessandrabettiol neweraofanticoagulationfactorxiandxiiinhibitors |